Clinical Trial Update: Sequential CAR-T Cells Targeting CD33/CD123 in Patients With Acute Myelocytic Leukemia AML [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/Phase 2 clinical trial evaluating sequential CAR-T cells targeting CD33 and CD123 in adults with acute myeloid leukemia is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• CD33/CD123-targeted CAR-T cells

Snippet

Sponsor: Essen Biotech | Conditions: AML, Acute Myeloid Leukemia | Phase 1, Phase 2 | Status: RECRUITING